A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI)

Journal of Pain and Symptom Management

Volumn 38, Issue 2, 2009, Pages 291-298

  Rao, Deepa ^a,b   Butt, Zeeshan ^a,b   Rosenbloom, Sarah ^a,b   Robinson Jr , Don ^c   Von Roenn, Jamie ^b   Kuzel, Timothy M ^b   Cella, David ^a,b  

^a Research and Education   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Johnson and Johnson Pharmaceutical Services   (United States)

Author keywords

Kidney cancer; measurement; patient reported outcomes; renal cell carcinoma

Indexed keywords

ADULT; ADVANCED CANCER; ADVANCED KIDNEY CANCER; ARTICLE; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; KIDNEY; KIDNEY CANCER; KIDNEY CARCINOMA; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PSYCHOMETRY; QUALITY OF LIFE; SCORING SYSTEM; SYMPTOM;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 67651177919     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2008.08.013     Document Type: Article

References (28)

1. American Cancer Society. Kidney cancer (adult)-Renal cell carcinoma (2008), American Cancer Society, Atlanta
2. Bukowski R., Cella D., Gondek K., and Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30 (2007) 220-227
3. Dhanda R., Gondek K., Song J., et al. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J Clin Oncol 24 18S (2006) 225s
4. Cella D., Cappelleri J.C., Bushmakin A., et al. Effects of sunitinib versus interferon-alfa in health-related quality of life in patients with metastatic renal cell carcinoma (MRCC): results from a randomized multinational phase III trial. Eur Urol Suppl 6 2 (2007) 238
5. Cella D., Li J., Cappelleri J.C., et al. Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN). J Clin Oncol 25 18S (2007) 345S
6. Eisen T., Bukowski R., Staehler S., et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. J Clin Oncol 24 Suppl 18 (2006) 4524
7. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
8. Williams G., Pazdur R., and Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat 14 (2004) 5-21
9. Cleeland C.S. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. Natl Cancer Inst Monogr 37 (2007) 16-21
10. Illman J., Corringham R., Robinson D., et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression?. J Support Oncol 3 1 (2005) 37-50
11. Kim H.L., Belldegrun A.S., Freitas D.G., et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 170 (2003) 1742-1746
12. Cleeland C., Gennett G.J., Dantzer R., et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97 (2003) 2919-2925
13. Victorson D., Soni M., and Cella D. Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer 106 (2006) 494-504
14. Brunelli C., Costantini M., Di Giulio P., et al. Quality-of-life evaluation: when do terminal cancer patients and health-care providers agree?. J Pain Symptom Manage 15 (1998) 151-158
15. Stromgren A.S., Groenvold M., Pedersen L., Olsen A.K., and Spile M. Does the medical record cover the symptoms experienced by cancer patients receiving palliative care? A comparison of the record and patient self-rating. J Pain Symptom Manage 21 (2001) 189-196
16. Lampic C., von Essen L., Peterson V.W., Larsson G., and Sjoden P.O. Anxiety and depression in hospitalized patients with cancer: agreement in patient-staff dyads. Cancer Nurs 19 (1996) 419-428
17. Passik S.D., Dugan W., McDonald M.V., et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 16 (1998) 1594-1600
18. Harding G., Cella D., Robinson D., et al. Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index. Health Qual Life Outcomes 5 (2007) 34
19. Cella D., Yount S., Du H., et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4 (2006) 191-199
20. Cella D., Yount S., Brucker P.S., et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 10 (2007) 285-293
21. Cella D., Paul D., Yount S., et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 21 (2003) 526-535
22. Webster K., Cella D., and Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 1 (2003) 79
23. Cella D., and Nowinski C. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 83 12 Suppl 2 (2002) S10-S17
24. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11 (1993) 570-579
25. Rosenbloom S.K., Yount S.E., Yost K.J., et al. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: measurement compliance with regulatory demands. In: Farquhar I., Summers K., and Sorkin A. (Eds). The value of innovation: Impacts on health, life quality, and regulatory research (2007), Elsevier, Oxford
26. Ryan G., and Bernard H.R. Data management and analysis methods. In: Denzin N., and Lincoln Y. (Eds). Handbook of qualitative research. 2nd ed. (2000), Sage Publications, Thousand Oaks, CA
27. Zubrod C., Schneiderman M., Frei E., et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene. J Chronic Dis 11 (1960) 7-33
28. Butt Z., Rosenbloom S.K., Abernethy A.P., et al. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 6 5 (2008) 448-455